These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 37040265)
1. Real-world outcomes of niraparib treatment in patients with ovarian cancer: a multicenter non-interventional study in China. Li J; Yang J; Shou H; Zhang L; Huang X; Tang X; Zheng F; Liu F; Wen H; Yang H; Wang H; Li Z; Chen X; Ju X; Cheng X; Tang J; Zhang M; Wu X Cancer Commun (Lond); 2023 Jun; 43(6):716-719. PubMed ID: 37040265 [No Abstract] [Full Text] [Related]
3. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. Mirza MR; Benigno B; Dørum A; Mahner S; Bessette P; Barceló IB; Berton-Rigaud D; Ledermann JA; Rimel BJ; Herrstedt J; Lau S; du Bois A; Herráez AC; Kalbacher E; Buscema J; Lorusso D; Vergote I; Levy T; Wang P; de Jong FA; Gupta D; Matulonis UA Gynecol Oncol; 2020 Nov; 159(2):442-448. PubMed ID: 32981695 [TBL] [Abstract][Full Text] [Related]
4. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US. Wu L; Zhong L J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378 [TBL] [Abstract][Full Text] [Related]
5. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU; Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354 [TBL] [Abstract][Full Text] [Related]
6. Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. Barrington DA; Tubbs C; Smith HJ; Straughn JM; Senter L; Cohn DE Int J Gynecol Cancer; 2020 Oct; 30(10):1569-1575. PubMed ID: 32753559 [TBL] [Abstract][Full Text] [Related]
14. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial. Matulonis UA; Walder L; Nøttrup TJ; Bessette P; Mahner S; Gil-Martin M; Kalbacher E; Ledermann JA; Wenham RM; Woie K; Lau S; Marmé F; Casado Herraez A; Hardy-Bessard AC; Banerjee S; Lindahl G; Benigno B; Buscema J; Travers K; Guy H; Mirza MR J Clin Oncol; 2019 Dec; 37(34):3183-3191. PubMed ID: 31518175 [TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy. Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751 [TBL] [Abstract][Full Text] [Related]
17. Niraparib - A promising drug with hematological toxicity. Patibandla NS; Monga DK J Oncol Pharm Pract; 2019 Oct; 25(7):1749-1753. PubMed ID: 30293481 [TBL] [Abstract][Full Text] [Related]
18. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572 [TBL] [Abstract][Full Text] [Related]
19. Identifying the need to refine the potential patient risk factors for niraparib-induced thrombocytopenia. Smith JA; Le T; Martin GA; Gaikwad A; Sun CH; Nugent EK; Lucci JA Gynecol Oncol; 2019 Feb; 152(2):265-269. PubMed ID: 30466807 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer. Longoria TC; Tewari KS Expert Opin Drug Metab Toxicol; 2018 May; 14(5):543-550. PubMed ID: 29620474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]